Table 2.
Patient baseline characteristics and therapy history: FAS
| Fosaprepitant group (n = 328) | Aprepitant group (n = 317) | p value | |
|---|---|---|---|
| Age, median (range) | 55 (20–79) | 53 (18–74) | .084 |
| Sex | |||
| Male | 163 (49.70) | 163 (51.42) | .694 |
| Female | 165 (50.30) | 154 (48.58) | |
| ECOGa | |||
| 0 | 64 (19.57) | 64 (20.19) | .939 |
| 1 | 251 (76.76) | 238 (75.08) | |
| 2 | 12 (3.67) | 15 (4.73) | |
| Prior chemotherapy | |||
| No | 121 (36.89) | 123 (38.80) | .627 |
| Yes | 207 (63.11) | 194 (61.20) | |
| Prior radiotherapy | |||
| No | 244 (74.39) | 256 (80.76) | .059 |
| Yes | 84 (25.61) | 61 (19.24) | |
| Cisplatin‐contained | |||
| No | 65 (19.8) | 83 (26.2) | .055 |
| Yes | 263 (80.2) | 234 (73.8) | |
FAS, full analysis set.
a
One data missing in Fosaprepitant group.